Ionis Pharmaceuticals (IONS) Non-Current Deffered Revenue (2009 - 2026)

Ionis Pharmaceuticals' Non-Current Deffered Revenue history runs 18 years deep, the most recent figure standing at $75.7 million for Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue fell 46.16% year-over-year to $75.7 million in Q1 2026; TTM through Mar 2026 was $75.7 million, a 46.16% decrease from a year earlier, with the FY2025 full-year figure at $92.0 million, down 41.21% from the prior year.
• Non-Current Deffered Revenue fell to $75.7 million in Q1 2026 per IONS's latest filing, from $92.0 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $333.1 million in Q1 2022 and bottomed at $75.7 million in Q1 2026.
• The 5-year median for Non-Current Deffered Revenue is $215.1 million (2024), against an average of $207.3 million.
• Across the five-year window, Non-Current Deffered Revenue declined 15.4% in 2023 and slumped 46.16% in 2026, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $287.8 million in 2022, then fell by 16.19% to $241.2 million in 2023, then tumbled by 35.11% to $156.5 million in 2024, then plunged by 41.21% to $92.0 million in 2025, then dropped by 17.67% to $75.7 million in 2026.
• Per Business Quant, the three latest IONS Non-Current Deffered Revenue figures stand at $75.7 million (Q1 2026), $92.0 million (Q4 2025), and $107.9 million (Q3 2025).